• Welcome, Guest. Please login or register.
    May 07, 2021, 07:27:43 AM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal thalpal.com Ā© A. Battaglia 2021





55477 Posts in 5941 Topics by 6281 Members
Latest Member: Rawlscr1

We love you, Lisa.
May you Rest in Peace,
knowing that your legacy lives on,
right here, and through all of us.
You're forever in our hearts.
« previous next »
Pages: 1 Go Down Print
Author Topic: Iron Balance Study in Weill Cornell Medical Center of New York  (Read 4940 times)
Gabri
Active Member
**
Offline Offline

Posts: 70


« on: November 04, 2008, 05:09:10 PM »

Hi folks,


I've heard about an trial that will be started in near future. Volunteers are wanted

Quote
Purpose

Subjects with thalassemia major require regular transfusion therapy to sustain life. The iron present in the transfused blood remains in the body where it can cause a variety of organ dysfunctions. Lifelong iron chelation therapy is needed to maintain iron balance but its effectiveness varies greatly. Like that of deferoxamine (Desferal, DFO) the mainstay of chelation therapy for 30 years, the effectiveness of deferasirox (Exjade, ICL670), the newly approved, orally effective iron chelating drug, is not satisfactory in all subjects. Even with good compliance, the iron excretion induced by a given drug exhibits wide subject-to-subject variability. There is often persistent iron overload of extra hepatic tissues such as the heart and pancreas leading to cardiac disease and diabetes. Combining the drugs may be a better approach in those subjects at increased risk. The iron balance studies proposed will permit an assessment of the potential of such a combination to place subjects in net negative iron balance and the relative effectiveness of the combination in relation to that of the individual drugs, an additive effect being expected. With such information, physicians will be able to design individualized chelation regimens that maximize effectiveness while minimizing side effects by adjusting the ratio and/or the dosing schedule of the two drugs.

For more infos look to this site:

http://www.clinicaltrials.gov/ct2/show/NCT00738413?term=weill&recr=Open&cond=%22Hematologic+Diseases%22&rank=2

God bless you all
Logged
Sharmin
Global Moderator
Supreme Member
*****
Offline Offline

Location: Canada

Gender: Female
Posts: 4155


Little A


« Reply #1 on: November 04, 2008, 05:27:15 PM »

I would highly recommend joining this study.  Many centers are prescribing combination therapy anyway, I think that you get maximum care and attention when you are part of a study.  Nothing removes iron as effectively and efficiently as combination therapy.

Sharmin
Logged

Sharmin
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8719


Will thal rule you or will you rule thal?


« Reply #2 on: November 04, 2008, 05:45:39 PM »

Sharmin has mentioned something that patients may overlook when thinking about participating in a study. You will not only get a chance to try what is a very promising chelation combination, but will also be under very close monitoring which can be of great benefit to iron overloaded patients,
Logged

Andy

All we are saying is give thals a chance.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!